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Abstract
Objective: To determine screening performance of maternal, fetal and placental char-
acteristics for selecting pregnancies at risk of gestational hypertension and pre-
eclampsia in a low-risk multi-ethnic population.
Method: In a prospective population-based cohort among 7124 pregnant women,
we collected maternal characteristics including body mass index, ethnicity, parity,
smoking and blood pressure in early-pregnancy. Fetal characteristics included second
and third trimester estimated fetal weight and sex determined by ultrasound. Placen-
tal characteristics included first and second trimester placental growth factor concen-
trations and second and third trimester uterine artery resistance indices.
Results: Maternal characteristics provided the best screening result for gestational
hypertension (area-under-the-curve [AUC] 0.79 [95% Confidence interval {CI}
0.76-0.81]) with 40% sensitivity at 90% specificity. For preeclampsia, the maternal
characteristics model led to a screening performance of AUC 0.74 (95% CI 0.70-0.78)
with 33% sensitivity at 90% specificity. Addition of second and third trimester pla-
cental ultrasound characteristics only improved screening performance for pre-
eclampsia (AUC 0.78 [95% CI 0.75-0.82], with 48% sensitivity at 90% specificity).
Conclusion: Routinely measured maternal characteristics, known at the start of preg-
nancy, can be used in screening for pregnancies at risk of gestational hypertension or
preeclampsia within a low-risk multi-ethnic population. Addition of combined second
and third trimester placental ultrasound characteristics only improved screening for
preeclampsia.
Received: 22 November 2019 Revised: 3 March 2020 Accepted: 4 March 2020
DOI: 10.1002/pd.5683
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
Prenatal Diagnosis. 2020;1–12. wileyonlinelibrary.com/journal/pd 1
1 | INTRODUCTION
Gestational hypertensive disorders (GHD) are common complications
affecting 5% to 10% of pregnancies and are major risk-factors for
maternal and fetal mortality and morbidity.1-4 Up to 50% of women
with gestational hypertension will be diagnosed with preeclampsia.5
Screening for women at risk of GHD may provide an opportunity for
intensified monitoring, leading to earlier diagnosis and possible inter-
ventions before severe disease develops.
Several maternal, fetal and placental characteristics are associated
with the risks of GHD.5-9 First trimester screening models for GHD
have been developed, using different screening parameters.10 “Sim-
ple” first trimester screening models mainly consist of maternal char-
acteristics such as age, body mass index (BMI), parity, and medical or
obstetric history.11 More advanced first trimester screening models,
which next to maternal characteristics often consist of biophysical
and biochemical parameters, such as uterine artery pulsatility index
(UtA-PI), mean arterial pressure (MAP) and biomarkers, report higher
area-under-the-receiver-operating-characteristic (ROC) curves.6,12
Performances of these advanced parameters vary among studies,
which may be partly explained by differences in population character-
istics. Many studies have focused on Caucasian women and specifi-
cally selected high-risk women, including multiparous women with
previous pregnancy complications, nulliparous women or women with
a high BMI. Restrictions to specific populations limit translation to
clinical practice, and replication of obtained screening performance
remains challenging.
We first assessed the potential of routinely measured maternal
characteristics known in early-pregnancy, for screening of gestational
hypertension and preeclampsia within a multi-ethnic population-
based prospective cohort study among 7124 low-risk pregnancies.
Next, we further explored whether the addition of detailed fetal
biometry measurements, placental Doppler vascular resistance
indices and placental biomarkers, obtained throughout pregnancy,
further improved screening of gestational hypertension and
preeclampsia.
2 | METHODS
2.1 | Study design
This study was embedded in the Generation R Study, a population-
based prospective cohort study from early-pregnancy onwards in
Rotterdam, the Netherlands.13 The study was approved by the local
Medical Ethical Committee (MEC 198.782/2001/31). Written consent
was obtained from participating women. Pregnant women were
enrolled between 2001 and 2006. Response rate at birth was 61%. In
total, 8879 women were enrolled during pregnancy. We excluded
non-singleton live-births, women with pre-existing hypertension and
women without information on GHD, leading to 7124 pregnant
women (Figure S1).
2.2 | Maternal, fetal and placental characteristics
used for screening
2.2.1 | Maternal characteristics in early-pregnancy
We selected maternal characteristics, known in early-pregnancy, asso-
ciated with GHD.14 Maternal age was assessed at enrolment and cate-
gorized: <25.0 years, 25.0 to 34.9 years and ≥35.0 years.15 Maternal
height and weight were measured without shoes and heavy clothing
at enrolment. BMI was calculated and categorized: normal weight
(BMI < 25 kg/m2), overweight (BMI 25.0-30.0 kg/m2) and obese (BMI
≥ 30.0 kg/m2).16 Information about ethnicity (categorized as previ-
ously described), parity (nulliparous or multiparous) and smoking sta-
tus (non-smoking, early-pregnancy-only and continued smoking) was
obtained at enrolment by questionnaire.14,15,17,18 Blood pressure was
measured at a median 13.8 (IQR 12.4-16.1) weeks gestation using
Omron-907 automated digital oscillometer sphygmomanometer
(OMRON Healthcare Europe, Hoofddorp, the Netherlands). The mean
value of two blood pressure readings over a 60-second interval was
documented.19,20 As blood pressure is part of the diagnosis of GHD,
only blood pressure measured <20th weeks gestation was used.
2.2.2 | Fetal characteristics
Ultrasound examinations were carried out in two dedicated research
centres in first (median 13.2 [IQR 12.2-14.7] weeks), second (median
20.5 [IQR 19.9-21.3] weeks) and third trimester (median 30.3 [IQR
29.8-30.9]weeks). We established gestational age from the first ultra-
sound examination.15 Estimated fetal weight (EFW) was calculated
What is already known on this topic?
• Several maternal, fetal and placental characteristics are
associated with the risks of gestational hypertension and
preeclampsia.
• Screening of the general population for gestational
hypertensive disorders in clinical practice remains highly
challenging.
What does this study add?
• Maternal characteristics known at the start of pregnancy
can be used for screening for gestational hypertensive
disorders.
• Addition of combined second and third trimester placen-
tal ultrasound screening results only improved screening
performance for preeclampsia, in addition to simple
maternal characteristics.
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according to Hadlock et al.21 Gestational age-adjusted standard-devi-
ation-scores (SDS) for EFW was based on reference growth charts
from the whole study population, and represent the equivalent of z-
scores.15 We defined screen-positive as EFW < 10th percentile in
second or third trimester.
2.2.3 | Placental characteristics
Uterine artery resistance index (UtA-RI) was derived from flow veloc-
ity waveforms in second and third trimester.22-25 We defined screen-
positive UtA-RI as UtA-RI SDS value in the highest decile. Placental
growth factor (PlGF) was measured in first and second trimester
maternal venous blood samples at a median of 13.2 (IQR 12.2-14.9)
and 20.3 (IQR 19.9-21.07), respectively.26,27 Gestational-age-adjusted
multiples of the medians (MoM) were calculated.26,27 Screen-positive
was defined as first or second trimester PlGF MoM in the lowest
decile.
2.3 | Gestational hypertensive disorders
Information about GHD was obtained from medical records.28 Occur-
rence of hypertension and related complications were cross-validated
using hospital registries, and defined using criteria of the International
Society for the Study of Hypertension in Pregnancy.28,29 Gestational
hypertension (n = 273, 3.8%) was defined as de-novo hypertension
(blood pressure ≥ 140/90 mmHg), appearing >20 weeks gestational
age. Preeclampsia (n = 149, 2.1%) was defined as de-novo hyperten-
sion (blood pressure ≥ 140/90 mmHg) after 20 weeks gestation with
concurrent proteinuria. As secondary outcome, we defined early-
onset preeclampsia (n = 14, 0.2%) as preeclampsia with a delivery
<34 weeks gestational age based on our available data.30 Any GHD
was defined as either gestational hypertension or preeclampsia.
2.4 | Statistical analyses
Because our study is focused on screening for GHD in a low-risk pop-
ulation, we aimed to use maternal, fetal and placental characteristics
which are obtained routinely or are simple and relatively cost-
effective to obtain where possible, to enable simple translation of
findings to clinical practice. Therefore, we first constructed a baseline
model, consisting of maternal characteristics known in early-
pregnancy and associated with GHD, including maternal age, BMI,
ethnicity, parity and smoking to assess the screening potential of a
simple maternal characteristics model. To evaluate the additional
effect of first trimester blood pressure, we added first trimester MAP,
per 10 mmHg, to the baseline model. Second, as fetal ultrasounds are
routinely available in second trimester and often in third trimester, we
added fetal parameters to the model: fetal sex and second trimester
and/or third trimester EFW screening result. Next, we added placental
parameters, which are not routinely available during pregnancy in
low-risk populations: second and/or third trimester UtA-RI screening
result and first and/or second trimester screening result of PlGF. We
assessed the variance explained for each logistic regression model.
We obtained predicted values from these regression models and
assessed model performance via ROC curves and calculation of area-
under-the-curve (AUC), along with the sensitivity at different false-
positive-rates (1-specificity). Positive predictive values (PPV) and
negative predictive values (NPV) and positive likelihood ratios (PLR)
and negative likelihood ratios (NLR) at a 10% false-positive-rate (90%
specificity) were calculated from the models. To compare model per-
formance of different models, we assessed whether the change in
effect size of obtained AUCs from the different models was clinically
relevant and statistically significant. Based on previous studies
focused on screening for similar adverse outcomes, we considered an
approximate 4% to 5% change in AUC as clinically relevant, as this
change is likely associated with a detectable increase in sensitiv-
ity.11,31,32 When model comparison fulfilled this criterion, we tested
whether this change was statistically significant using the test of
DeLong et al.33 When addition of a characteristic clinically and statis-
tically significantly improved screening performance of the model, this
characteristic was included and used as a new baseline model for fur-
ther analyses. Screening models were developed for gestational
hypertension and any preeclampsia separately. As secondary out-
come, we explored the screening performance of these characteristics
for early-onset preeclampsia separately. We performed two sensitivity
analyses to assess the robustness of our findings: (a) we assessed
model performance when we used “any gestational hypertensive dis-
order” as outcome; (b) we explored if we obtained similar screening
models if we added screening characteristics to the baseline model, in
order of their occurrence during pregnancy, instead of based on clini-
cal availability within a low risk population. Missing values were dealt
with by adding a missing category for each maternal and fetal charac-
teristic to the models, which resembles clinical practice. Analyses were
performed using Statistical Package of Social Sciences version 24.0
for Windows (IBM Corp., Armonk, New York).
3 | RESULTS
3.1 | Population characteristics
Table 1 shows population characteristics according to presence of
gestational hypertension or preeclampsia. Table S1 shows population
characteristics according to presence of early-onset preeclampsia and
any GHD.
3.2 | Screening for gestational hypertension using
maternal, fetal and placental characteristics
Maternal early-pregnancy characteristics had a moderate screening
performance for gestational hypertension (AUC0.73 [95% Confidence
interval {CI} 0.70-0.76]) (Figure 1). Model performance improved
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TABLE 1 Characteristics of mothers and their children (n = 7124)
Maternal characteristics
No gestational hypertensive
disorders n = 6702
Preeclampsia
n = 149 P-valuea
Gestational
hypertension n = 273 P-valueb
Age (years)
< 25, no. (%) 1364(20.4) 30(20.1) 0.07 47(17.2) 0.60
25–35, no. (%) 4364(65.1) 102(68.5) 188(68.9)
> 35, no. (%) 974(14.5) 17(11.4) 38(13.9)
Height, mean (SD) (cm) 167.3(7.3) 165.9(7.2) 0.03 168.8(6.9) <0.01
Weight, mean (SD) (kg) 68.3(12.5) 72(16.1) <0.01 78.4(17.8) <0.01
Body mass index, mean (SD) (kg/m2)
Normal, no. (%) 4298(64.1) 70(47.0) <0.01 115(42.1) <0.01
Overweight, no. (%) 1661(24.8) 47(31.5) 77(28.2)
Obese, no. (%) 698(10.4) 30(20.1) 79(28.9)
Education, no. higher education (%) 2720(40.6) 41(27.5) 0.05 108(39.5) 0.19
Race / ethnicity
Dutch or European, no. (%) 3232(58.2) 75(53.6) 0.18 198(73.6) <0.01
Surinamese, no. (%) 561(8.8) 19(13.6) 23(8.6)
Turkish, no. (%) 575(9.0) 11(7.9) 11(4.1)
Moroccan, no. (%) 431(6.7) 5(3.6) 8(3.0)
Cape Verdean or Dutch Antilles, no. (%) 469(7.3) 17(12.2) 12(4.5)
Parity, no. nulliparous (%) 3667(55.2) 117(79.1) <0.01 208(76.2) <0.01
Smoking, no. (%)
None, no. (%) 4265(72.1) 97(74.0) 0.09 173(70.0) 0.67
Early-pregnancy only, no. (%) 531(9.0) 17(13.0) 26(10.5)
Continued, no. (%) 1121(18.9) 17(13.0) 48(19.4)
Mean systolic blood pressure, median (IQR), mmHg 114(107-122) 120 (112-128) <0.01 124(116-132) <0.01
Mean diastolic blood pressure, median (IQR), mmHg 67(61-73) 73(66-80) <0.01 75(70-83) <0.01
Mean arterial pressure, median (IQR), mmHg 82.7(77.0-88.7) 88.3(81.4-95.3) <0.01 91.3(85-98.5) <0.01
Estimated fetal weight, mean (SD) (g)
Second trimester, mean (SD), SDS −0.15(0.96) −0.20(0.87) 0.52 0.00(1.08) 0.03
Second trimester, mean (SD), (g) 371(86) 376(90) 383(92)
Third trimester, mean (SD), SDS 0.00(0.98) −0.19(1.17) <0.01 0.15(1.18) 0.08
Third trimester, mean (SD), (g) 1612(255) 1550(249) 1639(255)
Placental growth factor
First trimester, median (IQR) MOM 1.01(0.76-1.35) 0.80(0.59-1.13) <0.01 0.92(0.68-1.15) 0.07
First trimester, median (IQR), ng/ml 43.5(29.2-73.0) 35.5(23.2-57.58) 35.2(26.4-60.0)
Second trimester, median (IQR), MOM 1.00(0.73-1.39) 0.71(0.50-1.11) <0.01 0.86(0.65-1.17) <0.01
Second trimester, median (IQR), ng/ml 199.3(145.4-286.9) 145.8(93.9-213.4) 174.0(131.6-244.1)
Uterine artery resistance index
Second trimester, mean (SD), SDS −0.01(0.99) 0.53(1.27) <0.01 0.02(1.10) 0.76
Second trimester, mean (SD) 0.54(0.09) 0.59(0.11) 0.54(0.10)
Third trimester, mean (SD), SDS −0.01(0.99) 0.75(1.43) <0.01 −0.14(1.00) 0.14
Third trimester, mean (SD) 0.48(0.08) 0.54(0.11) 0.47(0.08)
Abbreviation: IQR: inter quartile range.
Note: Values are observed data and represent means (SD), medians (IQR) or number of subjects (valid %). Differences in subject characteristics between
participants with and without gestational hypertensive disorders were evaluated using one-way ANOVA tests for continuous variables and chi-square tests
for categorical variables.
aP-value for comparison of population characteristics among women without gestational hypertensive disorders and with pre-eclampsia.
bP-value for comparison of population characteristics among women without gestational hypertensive disorders and with gestational hypertension.
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significantly when blood pressure was added (AUC 0.79 [95% CI
0.76-0.81], P-value for model comparison to maternal characteristics
model: 0.003). Using this model led to 40% sensitivity at 90%
specificity with PPV of 0.14, NPV of 0.97, PLR of 4, and NLR of 0.67.
Table S2 shows effect estimates for the maternal characteristics in
this model for the risk of gestational hypertension. The maternal
F IGURE 1 Legend on next page.
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characteristics model (with blood pressure in early-pregnancy) was
used as baseline model for further analyses. Addition of fetal or pla-
cental screening results to the maternal characteristics model did not
improve screening performance. When adding screening characteris-
tics in chronological order to the screening model for gestational
hypertension, the best model did not change (Figure S2).
3.3 | Screening for preeclampsia using maternal,
fetal and placental characteristics
Maternal characteristics model had a moderate screening perfor-
mance (AUC 0.70 [95% CI 0.66-0.74]) for preeclampsia (Figure 2).
Addition of blood pressure to the model led to a higher AUC (0.74
[95% CI 70-0.79]), but the difference was not statistically significant.
Using this model, we obtained a sensitivity of 33% at 90% specificity.
Table S2 shows the effect estimates for the included maternal charac-
teristics in this model for the risk of preeclampsia. Addition of fetal
characteristics did not improve screening for preeclampsia in compari-
son to the maternal characteristics model including early-pregnancy
blood pressure. Addition of both second and third trimester UtA-RI
led to a clinically improved screening performance (AUC 0.78 [95% CI
0.75 to 0.82]), sensitivity 48% at 90% specificity, PPV of 0.09, NPV of
0.99, PLR of 4.8, NLR of 0.58, P-value for comparison with maternal
characteristics model including early-pregnancy blood pre-
ssure < 0.01, Figure 2]. Subsequent addition of first or second trimes-
ter PlGF did not further improve model performance. Figure S2 shows
that when adding screening characteristics in chronological order to
the screening model for any preeclampsia, the addition of second tri-
mester PlGF clinically and significantly improved the maternal charac-
teristics with blood pressure model. Subsequent further addition of
second and third trimester UtA-RI improved model performance (AUC
0.80 [95% CI 0.77 to 0.84]). This obtained model did not perform bet-
ter in screening for preeclampsia than the obtained model based on
clinical availability including maternal characteristics, blood pressure
and second and third trimester UtA-RI only (P-value for compari-
son >0.05).
Maternal characteristics with blood pressure achieved a good per-
formance for the secondary outcome early-onset preeclampsia (AUC
0.86 [95% CI 0.78-0.94] with a sensitivity 57% at 90% specificity),
which was better than screening for preeclampsia at any gestational
age (Figure 3). Addition of third trimester EFW screening result, but
not other fetal or placental characteristics, clinically significantly
improved model performance (AUC 0.95 [95% CI 0.91-0.99], sensitiv-
ity 86% at 90% specificity, P-value for comparison to the maternal
characteristics model including early-pregnancy blood pressure:
0.039). When adding screening characteristics in chronological order
to the screening model for early-onset preeclampsia, the best model
did not change (Figure S3).
When we assessed screening for any GHD, we observed a mod-
erate model performance for maternal characteristics including blood
pressure (AUC 0.77 [95% CI 0.74-0.79], Figure S4). Addition of fetal
or placental characteristics did not improve screening. When adding
screening characteristics in chronological order to the screening model
for any GHD, the best model did not change (Figure S3).
4 | DISCUSSION
4.1 | Main findings
Maternal characteristics including age, BMI, ethnicity, parity, smoking
and blood pressure known in early-pregnancy have a moderate
screening performance for pregnancies at risk of gestational hyperten-
sion and preeclampsia in a low risk multi-ethnic population. Addition
of combined second and third trimester placental ultrasound screen-
ing results only improved screening performance for preeclampsia, in
addition to simple maternal characteristics.
4.2 | Interpretation of main findings
GHD are a major cause of maternal, fetal and neonatal morbidity and
mortality.2,3,5,7 It is well known that maternal, fetal and placental char-
acteristics are associated with GHD, but the strength of associations
of different factors varies across studies and populations.11,34,35
Based on these associations, screening models for GHD can be devel-
oped using groups of screening parameters, which may aid earlier
F IGURE 1 Screening performance for gestational hypertension based on maternal, fetal and placental characteristics. AUC, area under the
curve; CI, confidence interval; EFW, estimated fetal weight; PlGF, placental growth factor; UtA-RI, uterine artery resistance index. Values are
AUC (95% CI), Sensitivity at 70%, 80% and 90% specificity. †Maternal characteristics model: maternal age, BMI, ethnicity, parity and smoking;
Blood pressure model: Maternal characteristics model and first trimester mean arterial pressure per 10 mmHg. ‡Baseline model: maternal age,
BMI, ethnicity, parity and smoking, and first trimester MAP per 10 mmHg; Fetal sex model: Baseline model + fetal sex; second trimester EFW
model: Baseline model and second trimester estimated fetal weight <10th percentile; third trimester EFW model: Baseline model and third
trimester estimated fetal weight <10th percentile; second and third trimester EFW model: Baseline model, second and third trimester estimated
fetal weight <10th percentile. §Baseline model: maternal age, BMI, ethnicity, parity, smoking, and first trimester MAP per 10 mmHg; second
trimester UtA-RI model: Baseline model, second trimester uterine artery resistance index >90th percentile; third trimester UtA-RI model: Baseline
model, third trimester uterine artery resistance index >90th percentile; second and third trimester UtA-RI model: Baseline model, second and
third trimester uterine artery resistance index >90th percentile. First trimester PlGF model: Baseline model, first trimester placental growth factor
<10th percentile; second trimester PlGF model: Baseline model, second trimester placental growth factor <10th percentile; first and second
trimester PlGF model: Baseline model, first and second trimester placental growth factor <10th percentile [Colour figure can be viewed at
wileyonlinelibrary.com]
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identification of women at risk of GHD. However, screening of the
general population of pregnant women for GHD in clinical practice
remains highly challenging.
Previous studies have focused on using maternal characteristics
for the prediction of preeclampsia, whereas fewer studies have
focused on prediction of gestational hypertension.11,34,36-38 A previous
F IGURE 2 Legend on next page.
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systematic review among 29 studies, reporting on 70 models for pre-
diction of preeclampsia using routinely collected maternal characteris-
tics, showed that screening performance for preeclampsia at any
gestational age ranges from moderate (AUC 0.67 [95% CI 0.59-0.76])
to good (AUC 0.81 [95% CI 0.80-0.82]).11 The study with the highest
screening performance was conducted among 6015 mainly Caucasian
(74%) women and developed a screening model for preeclampsia at
any gestational age using maternal characteristics including ethnic ori-
gin, BMI, previous preeclampsia and family history of preeclampsia.37
A review among 92 studies, examining 25 356 688 pregnancies,
assessed risk of preeclampsia among women with and without individ-
ual clinical risk-factors determined <16 weeks gestation, to select risk-
factors for future development of prediction models.36 The authors
noted that for selection of pregnancies at risk of preeclampsia on a
population level, the use of common risk-factors may be more useful
than the use of rare but strongly associated risk-factors. These rare but
strong risk-factors could be more useful on an individual level.36 Fewer
studies developed models for prediction of gestational hypertension
using only maternal characteristics.37,38 The previously mentioned
study among 6015 women showed moderate screening performance
for gestational hypertension (AUC 0.69 [95% CI 0.68-0.70]), using a
model consisting of maternal characteristics including ethnic origin,
BMI, previous preeclampsia and family history of preeclampsia.37
We observed that routinely measured maternal characteristics in
early-pregnancy can be used in screening for risk of both gestational
hypertension and preeclampsia with sensitivity ranging from 33% to
40% at 90% specificity. Screening performance improved to 57% at
90% specificity, when we only focused on early-onset preeclampsia.
Screening performance of our screening model based on maternal
characteristics is quite comparable to previously developed models.11
The strength of our maternal characteristics model is that, in contrast
with most models which use previous preeclampsia, pre-existing con-
ditions or family history, we only used maternal characteristics rou-
tinely collected in clinical care, and as such are available early in
pregnancy. These characteristics can be used in low-resource settings
and are applicable for both nulliparous and parous women. Further-
more, in contrast to studies using tertiary or infertility care
populations, we fitted our maternal characteristics model on a low-risk
multi-ethnic population, which is more representative of the general
obstetric population. We used a similar model for prediction of gesta-
tional hypertension and preeclampsia, which may be easier to use in
clinical practice. Taken together, the current study shows that one
model consisting of routinely measured maternal characteristics
including blood pressure in early-pregnancy may be used to detect
pregnancies at risk of gestational hypertension and preeclampsia in a
low-risk multi-ethnic population and leads to a moderate screening
performance. This screening performance seems comparable to
screening models using more specific and rare maternal characteris-
tics, which may only be applicable in specific populations.
The value of fetal and placental characteristics in addition to
maternal characteristics for screening for GHD is debated. EFW has
been associated with GHD, and newborns born from pregnancies
complicated by preeclampsia have a 5% to 23% lower birthweight
compared newborns born after uncomplicated pregnancies.39-41 To
our knowledge, EFW has not been studied as predictor for gestational
hypertension or preeclampsia.39 In our study, addition of second or
third trimester EFW to maternal characteristics did not lead to better
screening performance for gestational hypertension and preeclampsia.
For early-onset preeclampsia, sensitivity did improve to 86% at 90%
specificity. This positive effect on screening performance may be
explained by reversed causation as fetal ultrasound was performed
around 30 weeks gestation. Although increased UtA impedance and
low PlGF have been described as predictors for GHD, evidence on
added value of these parameters is conflicting.11,12,42,43 A prospective
screening study for gestational hypertension and preeclampsia in a
low-risk multi-ethnic population among 8366 women created first tri-
mester models consisting of maternal history, blood pressure,
PAPP-A, and UtA-PI, and reported that there was a small contribution
of placental measurements. Model performance was better for
screening for preeclampsia than for gestational hypertension.12 A
recent study among 4212 nulliparous singleton pregnancies reported
that in addition to maternal characteristics, blood pressure, 20-week
UtA-PI, PAPP-A and PlGF did not improve screening performance for
early-onset preeclampsia.43 In our low-risk multi-ethnic population,
single addition of more advanced fetal and placental screening param-
eters did not improve screening for gestational hypertension and
F IGURE 2 Screening performance for preeclampsia based on maternal, fetal and placental characteristics. CI, confidence interval; EFW,
estimated fetal weight; PlGF, placental growth factor; UC, area under the curve; UtA-RI, uterine artery resistance index. Values are AUC (95% CI),
Sensitivity at 70%, 80% and 90% specificity. †Maternal characteristics model: maternal age, BMI, ethnicity, parity and smoking; Blood pressure
model: Maternal characteristics model and first trimester mean arterial pressure per 10 mmHg.‡Baseline model: maternal age, BMI, ethnicity,
parity and smoking, and first trimester MAP per 10 mmHg; Fetal sex model: Baseline model + fetal sex; second trimester EFW model: Baseline
model and second trimester estimated fetal weight <10th percentile; third trimester EFW model: Baseline model and third trimester estimated
fetal weight <10th percentile; second and third trimester EFW model: Baseline model, second and third trimester estimated fetal weight <10th
percentile.§Baseline model: maternal age, BMI, ethnicity, parity, smoking, and first trimester MAP per 10 mmHg; second trimester UtA-RI model:
Baseline model, second trimester uterine artery resistance index >90th percentile; third trimester UtA-RI model: Baseline model, third trimester
uterine artery resistance index >90th percentile; second and third trimester UtA-RI model: Baseline model, second and third trimester uterine
artery resistance index >90th percentile. Second and third trimester UtA-RI model and first trimester PlGF model: second and third trimester
UtA-RI model, first trimester placental growth factor < 10th percentile; second and third trimester UtA-RI model and second trimester PlGF
model: second and third trimester UtA-RI model, second trimester placental growth factor <10th percentile; second and third trimester UtA-RI
model and first and second trimester PlGF model: second and third trimester UtA-RI model, first and second trimester placental growth
factor < 10th percentile [Colour figure can be viewed at wileyonlinelibrary.com]
8 ERKAMP ET AL.
preeclampsia. Only when both second and third trimester UtA-
Doppler screening results were added simultaneously, screening per-
formance improved for preeclampsia only. The presence of screening
benefit of repeated UtA-RI results for preeclampsia but not for gesta-
tional hypertension is likely due to a larger role of the placenta in the
pathophysiology of preeclampsia.4 Because our study was specifically
focused on screening for GHD in low-risk pregnant populations, we
used routinely measured or easily available characteristics as much as
possible to enable translation of our findings to clinical practice and
low-resource settings. We, therefore, added screening characteristics
to the screening model based on clinical availability. However, earlier
screening for GHD allows potential earlier interventions. We further
explored whether addition of placental and fetal screening character-
istics in a chronological order led to different screening models.
F IGURE 3 Legend on next page.
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However, this did not affect our findings. We hypothesize that differ-
ences between screening performances of parameters in different
models may be due to the fact that maternal characteristics are strongly
correlated to GHD, but also with fetal and placental parameters, possi-
bly reducing screening potential of these more advanced fetal and
placental measurements.16,18,44 Thus, our results suggest that the addi-
tional screening benefit of fetal and placental parameters for screening
for gestational hypertension and preeclampsia is limited. Only when
both second and third trimester UtA-Doppler screening results were
added simultaneously, screening performance improved for preeclamp-
sia only. Use of fetal and placental measurements may have a larger
contribution to screening for GHD among higher risk populations.
Our study adds to existing evidence that maternal characteristics,
routinely measured in clinical practice, known early in any pregnancy,
can be used in screening for risk of gestational hypertension and pre-
eclampsia in low-risk multi-ethnic populations. It should be further
explored if maternal characteristics and MAP collected before preg-
nancy yield similar screening results to enable early risk selection and
modify risk-factors even before conception.45,46 Before any screening
model for GHD can be implemented in clinical practice, further
research is necessary. To date, aggregated analysis of screening
models was not possible due to large heterogeneity of studies. Future
large studies should test promising models in diverse populations, uti-
lizing maternal characteristics as much as possible, before adding more
advanced fetal and placental measurements, as maternal characteris-
tics are more easy and cost-effective to use in clinical practice and
can also be implemented in low-resource settings, in which GHD leads
to the poorest outcomes.47 In these studies, benefits due to identifica-
tion of true-positives vs harm caused by false-positives should be
evaluated in contemporary low-risk populations. For current clinical
practice, this study shows that maternal characteristics in early-
pregnancy contain valuable information for assessment of risk of
GHD, and should be considered in routine care.
4.3 | Strengths and limitations
We collected prospective data from early-pregnancy onwards in 7124
women with information regarding GHD. We defined diagnosis of
preeclampsia according to the 2001 ISSHP criteria.28,29 As no exact
gestational age at diagnosis of GHD was available, misclassification of
the onset of preeclampsia may have occurred. We considered it
important to specifically assess screening performance of our models
for early-onset preeclampsia, as this is often regarded as a different
entity with a higher risk of adverse outcomes. Our findings of a better
screening performance for early-onset preeclampsia are in line with
previous studies.11 However, as misclassification of gestational age at
diagnosis of preeclampsia may have occurred, early-onset preeclamp-
sia needs to be considered as secondary outcome and our models for
screening for early-onset preeclampsia need to be interpreted with
more caution and replicated among other study populations. Mea-
surements of blood pressure, ultrasound examinations and blood sam-
ples collection were performed according to the study protocol and
blinded with regard to pregnancy outcomes due to the prospective
nature of the study.48 Research findings were reported to healthcare
providers, which may have led to intensified monitoring or interven-
tions influencing the outcome and possibly effecting screening perfor-
mance. Current guidelines recommend low-dose Aspirin-prophylaxis
for women at higher risk of developing preeclampsia.49 Use of pro-
phylaxis likely influences occurrence of preeclampsia and could there-
fore influence obtained model performance of the screening models.
However, as our study participants were pregnant between 2001 and
2006, low-dose aspirin prophylaxis was not yet part of obstetric
guidelines. Thus, our screening models were not affected by low-dose
aspirin-prophylaxis among women at higher risk of preeclampsia. The
current population is not a clinical population, but a low-risk popula-
tion, which may have influenced screening performance.
4.4 | Conclusion
Routinely measured maternal characteristics and blood pressure in
early-pregnancy have a moderate screening performance for pregnan-
cies at risk of gestational hypertension and preeclampsia in a contem-
porary multi-ethnic, low-risk population. Addition of combined second
and third trimester placental ultrasound screening results only
improved screening performance for preeclampsia, in addition to sim-
ple maternal characteristics.
F IGURE 3 Screening performance for secondary outcome early-onset preeclampsia based on maternal, fetal and placental characteristics.
AUC, area under the curve; CI, confidence interval; EFW, estimated fetal weight; PlGF, placental growth factor; UtA-RI, uterine artery resistance
index. Values are AUC (95% CI), Sensitivity at 70%, 80% and 90% specificity. †Maternal characteristics model: maternal age, BMI, ethnicity, parity
and smoking; Blood pressure model: Maternal characteristics model and first trimester mean arterial pressure per 10 mmHg. ‡Baseline model:
maternal age, BMI, ethnicity, parity and smoking, and first trimester MAP per 10 mmHg; Fetal sex model: Baseline model + fetal sex; second
trimester EFW model: Baseline model and second trimester estimated fetal weight <10th percentile; third trimester EFW model: Baseline model
and third trimester estimated fetal weight <10th percentile; second and third trimester EFW model: Baseline model, second and third trimester
estimated fetal weight <10th percentile.§Baseline model: maternal age, BMI, ethnicity, parity, smoking, and first trimester MAP per 10 mmHg, and
third trimester EFW; second trimester UtA-RI model: Baseline model, second trimester uterine artery resistance index >90th percentile; third
trimester UtA-RI model: Baseline model, third trimester uterine artery resistance index >90th percentile; second and third trimester UtA-RI
model: Baseline model, second and third trimester uterine artery resistance index >90th percentile. First trimester PlGF model: Baseline model,
first trimester placental growth factor <10th percentile; second trimester PlGF model: Baseline model, second trimester placental growth factor
<10th percentile; first and second trimester PlGF model: Baseline model, first and second trimester placental growth factor <10th percentile
[Colour figure can be viewed at wileyonlinelibrary.com]
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